Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study
de Jong, Corine; Herder, Gerarda J.M.; Deneer, Vera H.M.
(2020) Thoracic cancer, volume 11, issue 12, pp. 3634 - 3640
(Article)
Abstract
Introduction: Platinum–based chemotherapy is currently the most frequently applied first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations or high PD-L1 expression. Unfortunately, chemotherapy-induced toxicity is prevalent and may affect patients' quality of life to a considerable extent. Presumably, genetic variants of genes, coding for
... read more
proteins involved in the processes of the development of toxicity, may be of interest as predictors of benefits and harms of platinum-based chemotherapy. The primary objective of the study is to investigate the influence of genetic variants on the incidence of chemotherapy-induced toxicity in patients with NSCLC undergoing first-line platinum-based chemotherapy. The main secondary objectives are to study the association between genetic variants and treatment response and to study the association between skeletal muscle mass (SMM) as well as patient-reported health-related quality of life (HRQOL) and treatment response and toxicity. Methods: In this multicenter prospective follow-up study, a total of 350 patients with NSCLC (stage II–IV) undergoing first-line platinum-based chemotherapy will be included. Blood samples for DNA isolation and genotyping, questionnaires and data on patients risk factors and disease stage will be recorded. The primary endpoint is chemotherapy-induced (non-)hematological toxicity, comprising; nephrotoxicity, neuropathy, esophagitis, ototoxicity, pneumonitis, gastrointestinal toxicity, anemia, leukocytopenia, neutropenia and thrombocytopenia. Secondary endpoints include dose-limiting toxicity, HRQOL, and treatment response (radiological response [RECIST 1.1] and overall survival [OS]). Discussion: Results of the PGxLUNG study will be primarily used to determine the influence of genetic variants on the incidence of chemotherapy-induced toxicity in patients with NSCLC undergoing first-line platinum-based chemotherapy.
show less
Download/Full Text
Keywords: carboplatin; cisplatine; chemotherapy-induced toxicity, genome-wide association study (GWAS), health-related quality of life (HRQOL);non-small cell lung cancer (NSCLC); skeletal muscle mass (SMM); Pharmacogenetics; platinum-based chemotherapy, chemotherapy-induced toxicity, platinum-based chemotherapy, Pharmacogenetics, cisplatine, skeletal muscle mass (SMM), carboplatin, non-small cell lung cancer (NSCLC), health-related quality of life (HRQOL), Oncology, Pulmonary and Respiratory Medicine
ISSN: 1759-7706
Publisher: Blackwell Publishing Asia Pty Ltd
Note: Funding Information: The authors would like to thank the local principle investigators S.W.A. van Haarlem MD (St. Antonius Hospital, Nieuwegein/Utrecht), F. van der meer MD (Diakonessenhuis, Utrecht/Zeist), A.S.R. van Lindert MD (University Medical Center Utrecht, Utrecht), A. ten Heuvel MD (Groene Hart Ziekenhuis, Gouda), J. Brouwer MD (Ziekenhuis Rivierenland, Tiel) and, R. van der Heide (St. Antonius Hospital, Nieuwegein/Utrecht) for his expert contribution and technical assistance regarding the genotyping. The authors received funding from the St Antonius Onderzoeksfonds and patient funding to conduct this study. Financial support for the genotyping was provided by Roche Nederland B.V. Roche Nederland B.V. will not be involved in the data collection, data analysis, or reporting of the results. Funding Information: The authors would like to thank the local principle investigators S.W.A. van Haarlem MD (St. Antonius Hospital, Nieuwegein/Utrecht), F. van der meer MD (Diakonessenhuis, Utrecht/Zeist), A.S.R. van Lindert MD (University Medical Center Utrecht, Utrecht), A. ten Heuvel MD (Groene Hart Ziekenhuis, Gouda), J. Brouwer MD (Ziekenhuis Rivierenland, Tiel) and, R. van der Heide (St. Antonius Hospital, Nieuwegein/Utrecht) for his expert contribution and technical assistance regarding the genotyping. The authors received funding from the St Antonius Onderzoeksfonds and patient funding to conduct this study. Financial support for the genotyping was provided by Roche Nederland B.V. Roche Nederland B.V. will not be involved in the data collection, data analysis, or reporting of the results. Publisher Copyright: © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
(Peer reviewed)
